Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14753935 | 0.82 | — | — | |
| SCHEMBL19542927 | 0.82 | POLB (0.32) | — | |
| SCHEMBL804973 | 0.81 | TGFBR1 (0.33) | — | |
| SCHEMBL11982315 | 0.77 | CA1 (0.31) | — | |
| SCHEMBL804954 | 0.77 | TSHR (0.42) | MAPK1TSHRALDH1A1 | |
| SCHEMBL21231186 | 0.77 | MTNR1A (0.37) | KDM4EMAPK1HIF1AMTNR1AMTNR1B | |
| SCHEMBL17019095 | 0.77 | CCNE2 (0.37) | KDM4EMAPK1HIF1AMTNR1AMTNR1B | |
| SCHEMBL15826836 | 0.73 | — | — | |
| SCHEMBL13975598 | 0.73 | TSHR (0.38) | TSHR | |
| SCHEMBL10076039 | 0.73 | ALDH1A1 (0.30) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673898-B2 | Substituted inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11649251-B2 | Substituted inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-10781218-B2 | Substituted inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20190092784-A1 | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE | KURA ONCOLOGY, INC. | 2019-03-28 | — | — | US | disclosed |
| EP-1315985-B1 | PROCESS FOR SURFACE MODIFYING SUBSTRATES AND MODIFIED SUBSTRATES RESULTING THEREFROM | NOVARTIS AG (CH) | 2017-07-26 | — | — | EP | disclosed |
| US-8672466-B2 | Ink composition, ink set and image forming method | FUJIFILM CORPORATION (JP) | 2014-03-18 | — | — | US | disclosed |
| US-20120069084-A1 | INK COMPOSITION, INK SET AND IMAGE FORMING METHOD | FUJIFILM CORPORATION (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649251-B2 | Substituted inhibitors of menin-MLL and methods of use | MLLT1, MEN1, MLLT3 | KDM4E 149/4885MAPK1 1106/4885HIF1A 3593/4885 |
| US-20190092784-A1 | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE | MLLT1, MEN1, MLLT3 | KDM4E 149/4885MAPK1 1106/4885HIF1A 3593/4885 |
| US-11673898-B2 | Substituted inhibitors of menin-MLL and methods of use | MLLT1, MEN1, MLLT3 | KDM4E 151/4885MAPK1 762/4885HIF1A 2530/4885 |
| US-10781218-B2 | Substituted inhibitors of menin-MLL and methods of use | MLLT1, MEN1, MLLT3 | KDM4E 125/4885MAPK1 497/4885HIF1A 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.